Shingles Vaccines

Shingles Vaccines

Global Shingles Vaccines Market to Reach US$4.5 Billion by 2030

The global market for Shingles Vaccines estimated at US$3.2 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Live-Attenuated Vaccines segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$868.6 Million While China is Forecast to Grow at 8.2% CAGR

The Shingles Vaccines market in the U.S. is estimated at US$868.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$928.2 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Shingles Vaccines Market - Key Trends and Drivers Summarized

How Do Shingles Vaccines Work and What Are Their Key Components?

Shingles vaccines are critical preventive tools designed to protect against herpes zoster, commonly known as shingles, a painful viral infection caused by the reactivation of the varicella-zoster virus—the same virus responsible for chickenpox. Once a person has had chickenpox, the virus remains dormant in the body, potentially reactivating later in life as shingles, particularly in older adults and those with weakened immune systems. Shingles vaccines work by boosting the body`s immune response to the virus, thereby reducing the likelihood of reactivation and the severity of symptoms if an outbreak does occur. The key components of these vaccines include inactivated viral particles or viral subunits that stimulate the immune system without causing illness. Modern shingles vaccines, such as the recombinant zoster vaccine (RZV), provide robust protection and are preferred due to their higher efficacy compared to older formulations. These vaccines are typically administered in a series of two doses, spaced several months apart, ensuring long-lasting immunity against the virus.

Who Needs Shingles Vaccines and Why Are They So Important?

Shingles vaccines are particularly important for adults aged 50 and older, as well as individuals with weakened immune systems, who are at increased risk of developing shingles and its complications, such as postherpetic neuralgia (PHN), a condition characterized by severe, long-lasting pain even after the shingles rash has healed. Vaccination is crucial because shingles can lead to significant discomfort, interfere with daily activities, and in severe cases, result in complications like vision loss if the rash occurs near the eyes. For older adults, the immune system`s ability to fight infections weakens with age, making vaccination an effective strategy to prevent shingles. Additionally, for individuals with conditions that compromise the immune system—such as cancer, HIV, or those on immunosuppressive therapies—shingles vaccines offer a proactive measure to mitigate the risk of a debilitating shingles outbreak. Public health organizations strongly recommend shingles vaccination as part of routine preventive care for eligible populations, emphasizing its role in maintaining health and quality of life in older adults.

What Are the Latest Innovations and Trends in Shingles Vaccines?

The field of shingles vaccines has seen significant advancements, with ongoing research focused on improving efficacy, accessibility, and patient compliance. One of the most notable trends is the development of recombinant vaccines, such as the adjuvanted recombinant zoster vaccine, which provides higher protection rates and longer-lasting immunity compared to the older live attenuated vaccines. These recombinant vaccines are particularly advantageous for immunocompromised individuals who may not be suitable candidates for live vaccines. Another trend is the increasing availability of combination vaccines that protect against multiple diseases, including shingles, in a single shot, which can improve vaccination rates by simplifying the immunization process. Additionally, there is growing interest in expanding vaccination recommendations to younger populations at risk, such as those with autoimmune diseases or those undergoing organ transplants. Furthermore, ongoing research aims to develop vaccines that provide protection with fewer doses or enhanced formulations that offer even longer protection. These innovations are making shingles vaccines more effective and accessible, contributing to broader public health efforts to reduce the burden of herpes zoster.

What Is Driving the Growth of the Shingles Vaccines Market?

The growth in the shingles vaccines market is driven by several factors that reflect the increasing recognition of the importance of vaccination in preventing this painful and potentially debilitating condition. One of the primary drivers is the aging global population, which is more susceptible to shingles and its complications, leading to a higher demand for vaccination among older adults. Technological advancements in vaccine development, particularly the shift towards more effective recombinant vaccines, are also fueling market growth by providing safer and more reliable options for a broader range of patients. Public health initiatives and recommendations from health authorities, such as the CDC and WHO, are propelling the adoption of shingles vaccines, as these organizations advocate for routine vaccination to prevent the significant healthcare costs and personal suffering associated with shingles. Additionally, increased awareness of the long-term effects of shingles, such as postherpetic neuralgia, is encouraging more individuals to seek vaccination. The expansion of healthcare access in emerging markets, along with growing government support for vaccination programs, is also contributing to the rising demand for shingles vaccines globally.

Select Competitors (Total 35 Featured) -

• Barinthus Biotherapeutics plc
• CanSino Biologics Inc.
• Chongqing Zhifei Biological Products Co., Ltd
• CSL Seqirus
• Curevo Inc.
• Geneone Life Science
• GSK plc
• INVC Wellness Pvt. Ltd
• Jiangsu Recbio Technology Co., Ltd
• Merck & Co., Inc.
• Pfizer inc
• RxDx Healthcare
• SK bioscience
• SK chemicals

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.